Status:
RECRUITING
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Stage IV Non-small Cell Lung Cancer
Targeted Therapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE fea...
Detailed Description
This research study involves an intervention consisting of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues an...
Eligibility Criteria
Inclusion
- Age 18 or older
- MGH Cancer Center patient
- Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET)
- Receiving targeted therapy
- Ability to respond in English or Spanish
Exclusion
- Cognitive impairment or serious mental illness that limits ability to provide informed consent
- Need for urgent palliative care or hospice referral
- Pregnant women
- Prisoners
Key Trial Info
Start Date :
September 29 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04900935
Start Date
September 29 2023
End Date
September 1 2027
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115